

- requirements of the Swiss Institute for Education and Continuing Medical Education.
- 1995-2022 Medical student instruction in clinical skills in Internal Medicine and Rheumatology, subject-oriented tutorials in Rheumatology, lectures in Rheumatology and Immunology, University of Basel.
- 1995-1996 Instruction of Internal Medicine for physiotherapy students, Physiotherapy School, Basel.
- 1984-1987 Specification of study catalogue for the School of Nursing, Bürgerspital, Solothurn, Switzerland.

6. Honors

- 1994 Boots Swiss Rheumatology Prize

7. Society Memberships

Swiss Medical Association
 Medical Association of the Canton of Aargau
 Swiss Society for General Internal Medicine
 Swiss Society for Rheumatology
 Swiss Society for Allergy and Immunology
 American College of Rheumatology
 European League against Rheumatism (EULAR)

8. Other Functions

Member of the Medical Faculty, University of Basel
 Past Lecturer at the Department of Health Sciences and Technology, ETHZ
 Past President and Member of the Scientific Committee of the Swiss Society for Rheumatology
 Founding and past member of the board of the Swiss Clinical Quality Management in Rheumatoid Arthritis (SCQM) Foundation
 Past Editor, Seminars in Immunopathology, Springer Nature
 Grant reviews
 Peer reviews
 Scientific consultant for pharmaceutical companies
 Past Member, Ethics Committee of the Canton of Aargau

9. Publications

9.1. Peer Reviewed Publications

1. Defective cAMP-dependent phosphorylation of intact T lymphocytes in active systemic lupus erythematosus. Hasler P, Schultz LA, Kammer GM. Proc Natl Acad Sci USA 1990;87:1978-82.
2. cAMP-dependent protein kinase A in chondrocyte cultures: holoenzyme activation, phosphorylation of cellular proteins, effects of NSAIDs and possible role in proteoglycan synthesis. Malemud CJ., Papay R, Hasler P, Kammer GM Semin Arthr Rheum 1990;19:10-5 (Suppl).
3. Ist die Kochsalziodierung noch nötig? Supersaxo Z, Selz B, Hasler P, Wespi HJ, Abelin T, Bürgi H. Schweiz Med Wschr 1991;121:317-23.
4. Ribosomal P proteins P0, P1 and P2 are phosphorylated by casein kinase II at their conserved carboxyl-termini. Hasler P, Brot N, Weissbach H, Parnassa AP, Elkon KB. J Biol Chem 1991;266:13815-20.
5. Human T lymphocyte cAMP-dependent protein kinase: Subcellular distributions and activity ranges of type I and Type II isozymes. Hasler P, Moore JJ, Kammer GM. FASEB J. 1992;6:2735-41.
6. The effect of circulating serum factors from patients with systemic lupus erythematosus on protein kinase A (PKA) activity and PKA-dependent protein phosphorylation in T lymphocytes. Kammer GM, Haqqi TM, Hasler P, Malemud CJ. Clin Immunol Immunopathol. 1993;67:8-16.
7. Insufficiency fractures of the sacrum: 20 cases and review of the literature. Weber M, Hasler P, Gerber H. Spine 1993;18:2507-12.
8. The effect of nonsteroidal anti-inflammatory drugs on cAMP-dependent protein kinase phosphorylation in human chondrocyte cultures. Malemud CJ, Papay RS, Hasler P, Kammer GM. Clin Exp Rheumatol. 1994;12:149-56.
9. The effect of phosphorylation and site-specific mutations of the immunodominant epitope of the ribosomal P proteins on the binding of anti-P autoantibodies. Hasler P, Blount, Y, Brot N, Weissbach H, Elkon KB. Clin Immunol Immunopathol. 1994;72:273-79.
10. Vasculitides in hairy-cell leukemia. Hasler P, Kistler H, Gerber H. Semin Arthr Rheum 1995;25:134-42.
11. A woman with panic attacks and double vision who liked cheese. Vogt T, Hasler P. Lancet 1999;354:300.

12. Feasibility of the RADAI, a self-administered rheumatoid arthritis activity index. Fransen J., Langenegger T., Michel B.A., Stucki G. for the members of the Swiss Clinical Quality Management in Rheumatoid Arthritis. *Rheumatology* 2000;39:321-27.
13. Clinical quality management in rheumatoid arthritis: putting theory into practice. Uitz E., Fransen J., Langenegger T., Stucki G. for the members of the Swiss Clinical Quality Management in Rheumatoid Arthritis. *Rheumatology* 2000;39:542-49.
14. B cell receptor signaling and autoimmunity. Hasler P, Zouali M. *FASEB J* 2001;15:2085-2098.
15. Der Nachweis von Autoantikörpern gegen extrahierbare nukleäre Antigene (ENA) mittels Line Immunoassay (LIA) im Vergleich mit dem Enzyme-Linked Immunosorbent Assay (ELISA) in Relation zu anderen Laborparametern und zur Klinik. Maclachlan D, Vogt P, Rose L, Wu X, Tyndall A, Hasler P. *Z Rheumatologie* 2002;61:534-44.
16. Posterior tibial tendon dysfunction and MRI-imaging in rheumatoid arthritis. Hasler P, Meier M, Hintermann B. *Rheumatol Int* 2002;22:38-40.
17. Subversion of B lymphocyte signaling by infectious agents. Hasler P, Zouali M. *Genes and Immunity* 2003;4:95-103.
18. Meeting Highlights. *Frontiers in Autoimmunity: Fundamental Aspects and Clinical Perspectives*. NATO Advanced Study Institute, Keszthely, Hungary 2002. Hasler P, Zouali M. *Expert Opin Ther Targets* 2003;7:125-130.
19. Arthritis and interstitial granulomatous dermatitis (Ackerman Syndrome) with pulmonary silicosis. Kroesen S, Itin P, Hasler P. *Semin Arthr Rheum* 2003;32:334-40.
20. Serious bacterial infections under anti-TNF therapy. Kroesen S, Widmer A, Tyndall A, Hasler P. *Rheumatology* 2003;42:617-21.
21. Efficacy and safety of 4 doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A 4-week multicenter, randomized, double-blind, placebo-controlled trial. Schnitzer T, Beier J, Geusens P, Hasler P, Patel SK, Senftleber I, Gitton X, Jayawardene S, Sloan VS, Poor G. *Arthritis Rheum* 2004;51:549-57.
22. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. Bassetti S, Wasmer S, Hasler P, Vogt T, Nogarth D, Frei R, Widmer AF. *J Rheumatol*. 2005;32:2125-9.
23. Immune receptor signaling, aging and autoimmunity. Hasler P, Zouali M. *Cell Immunol* 2005;233:102-108.
24. Biological Therapies Directed Against Cells in Autoimmune Disease. Hasler P. *Semin Immunopathol* 2006;27:443-56.
25. B lymphocytes as therapeutic targets in systemic lupus erythematosus. Hasler P, Zouali M. *Expert Opin Ther Targets* 2006;10:803-815.
26. Occurrence of neutrophil extracellular DNA traps (NETs) in pre-eclampsia: a link with elevated levels of cell-free DNA? Gupta AK, Hasler P, Gebhardt GS, Holzgreve W, Hahn S. *Ann N Y Acad Sci* 2006;1075:118-22.
27. Occurrence of neutrophil extracellular DNA traps (NETs) in pre-eclampsia: a link with elevated levels of cell-free DNA? Gupta AK, Hasler P, Gebhardt GS, Holzgreve W, Hahn S. *Ann N Y Acad Sci* 2006;1075:118-22.
28. Hörverlust nach Myelographie. Schiffer P, Podvinec M, Hasler P. *Praxis Schweiz Rundschau Medizin* 2006;95:369-73.
29. Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. Gupta A., Hasler P, Holzgreve W, Gebhardt S, Hahn S. *Human Immunol* 2006;66:1146-54.
30. Occurrence of neutrophil extracellular traps (NETs) in pre-eclampsia. A link with elevated levels of cell-free DNA? Gupta A, Hasler P, Gebhardt S, Holzgreve W, Hahn S. *Ann NY Acad Sci* 2006;1075:118-22.
31. Chronische, erosive Polyarthrit mit lumbalen Rückenschmerzen und chronisch rezidivierenden Oberbauchschmerzen. Iseli A., Hüllstrung HD, Hasler P. *Schweiz Rundsch Med Prax* 2006;95:287-90.
32. Detection of tuberculosis by extensive screening in a patient with rheumatoid arthritis prior to anti-TNF-alpha therapy. Iseli A, Hüllstrung HD, Rodenhausen S, Widmer FA, Tyndall A, Hasler P. *Rheumatology* 2006;45:1049-50.
33. Protein microarray platform for the multiplex analysis of biomarkers in human sera. Urbanowska T, Mangialaio S, Zickler C, Cheevapruk S, Hasler P, Regenass S, Legay F. *J Immunol Methods* 2006;316:1-7.
34. Complete recovery of visual acuity in two patients with giant cell arteritis. Jaggi GP, Lüthi U, Forrer A, Hasler P, Killer HE. *Swiss Med Wkly* 2007;137:265-8.
35. Increased concentrations of antibody-bound circulatory cell-free DNA in rheumatoid arthritis. Zhong XY, Li Y, von Mühlönen I, Hristoskova S, Kang A, Tyndall A, Holzgreve W, Hahn S, Hasler P. *Clin Chem* 2007;53:1609-14.
36. Neutrophil NETs: a novel contributor to preeclampsia-associated placental hypoxia? Gupta AK, Hasler P, Holzgreve W, Hahn S. *Semin Immunopathol* 2007;29:163-7.
37. Safety and efficacy of biologics directed against TNF-alpha and CD20 in the therapy of vasculitis and systemic lupus erythematosus. Walker UA, Hasler Paul Ther Umschau 2008;65:303.
38. Hemophagocytic syndrome in adult-onset Still's disease (AOSD): A must for biologics? – Case report and brief review of the literature. Bürgi U, Mendez A, Hasler P, Hüllstrung HD. *Rheumatol Int* 2012;32:3269.
39. Gupta AK, Joshi MB., Philippova M, Erne P, Hasler P, Hahn S, Resink TJ. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death *FEBS Lett* 2010;584:3193.
40. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. Avouac J, Walker U, Tyndall A, et al *J. Rheumatol* 2010;37:1488-501.

41. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, Allanore Y, Distler O, Riemekasten G, Valentini G, Müller-Ladner U; EUSTAR Co-authors. *Ann Rheum Dis* 2012;71:1355.
42. HORIZON Pivotal Fracture Group Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, Man Z, Hadji P, Reid IR; *J Bone Miner Res* 2011;26:984.
43. Mononeuritis multiplex under the TNF-alpha inhibitor infliximab. Bandelow N, Wiederkehr M, Hasler P. *Praxis* 2011;100:241-3.
44. Refractory neuro-Behcet treated by tocilizumab: Case report. Urbaniak P, Hasler P, Kretzschmar S. *Clin Exp Rheumatol* 2012;30 Suppl 72:S73-5.
45. Reactive arthritis. Ryser C, Hasler P. *Praxis* 2010;99:1317-26.
46. Use of abatacept in rheumatoid arthritis. von Kempis J, Dudler J, Hasler P, Kyburz D, Tyndall A, Zufferey P, Villiger PM. *Swiss Med Wkly* 2012; 11;142.
47. Neutrophil NETs in reproduction: from infertility to preeclampsia and the possibility of fetal loss. Hahn S, Giaglis S, Hoesli I, Hasler P. *Front Immunol* 2012;3:362.
48. Fractures associated with diminished bone density, hypercalciuria and osteolysis. Is the diagnosis osteoporosis or a syndrome? Neuwirth A, Geeser A, Hasler P. *Praxis* 2012;101:413.
49. Modulation of neutrophil NETosis: interplay between infectious agents and underlying host physiology. Hahn S, Giaglis S, Chowdhury CS, Hoesli I, Hasler P. *Semin Immunopathol* 2013;35:439
50. Special issue on neutrophils. Hasler P, Hahn S. *Semin Immunopathol*. 2013;35:375-6.
51. Modulation of neutrophil NETosis: interplay between infectious agents and underlying host physiology. Hahn S, Giaglis S, Chowdhury CS, Hoesli I, Hasler P. *Semin Immunopathol* 2013;35:439.
52. Cell-free nucleic acids in (maternal) blood: any relevance to (reproductive) immunologists? Hahn S, Giaglis S, Buser A, Hoesli I, Lapaire O, Hasler P. *J Reprod Immunol* 2014;pii: S0165-0378.
53. Biological agents in monotherapy for the treatment of rheumatoid arthritis. Gabay C., Hasler P, Kyburz D, So A., Villiger P, von Kempis J, Walker U. *Swiss Med Wkly* 2014;144:w13950.
54. Efficient neutrophil extracellular trap induction requires mobilization of both intracellular and extracellular calcium pools and is modulated by cyclosporine A. Gupta AK, Giaglis S, Hasler P, Hahn S. *PLoS ONE* 2014;9(5): e97088. doi:10.1371/journal.pone.0097088.
55. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: Analysis of underlying signal transduction pathways and potential diagnostic utility. Sur Chowdhury C, Giaglis S, Walker UA, Buser A, Hahn S, Hasler P. *Arthritis Res Ther* 2014;doi:10.1186/ar4579.
56. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Avouac J, Walker UA, Hachulla E, Riemekasten G, Cuomo G, Carreira PE, Caramaschi P, Ananieva LP, Matucci-Cerinic M, Czirjak L, Denton C, Ladner UM, Allanore Y; the EUSTAR collaborators. *Ann Rheum Dis* 2014 doi:10.1136/annrheumdis-2014-205295.
57. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kötter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quéré I, Rich É, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socié G, Gratwohl A, Tyndall A; EBMT/EULAR Scleroderma Study Group. *JAMA* 2014 Jun 25;311:2490-8.
58. The dermatologist's role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologists. Boehncke W-H, Anliker MD, Conrad C, Dudler J, Hasler P, Hasler P, Häusermann P, Kyburz D, Laffitte E, Michel BA, Möller B, Navarini AA, Villiger PM, Yawalkar N, Gabay C. *Dermatology* 2015;230:75.T
59. The advent of biosimilars: challenges and risks. Müller R, Renner C, Gabay C, Cassata G, Lohri A, Hasler P. *Swiss Med Wkly* 2014 Jul 1;144:w13980.
60. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Mihai C, Landewé R, van der Heijde D, Walker UA, Constantin PI, Gherghe AM, Ionescu R, Rednic S, Allanore Y, Avouac J, Czirjak L, Hachulla E, Riemekasten G, Cozzi F, Airò P, Cutolo M, Mueller-Ladner U, Matucci-Cerinic M; EUSTAR co-authors. *Ann Rheum Dis* 2016 Apr;75(4):681-6.
61. Elevated Levels of Total Cell-Free DNA in Maternal Serum Samples Arise from the Generation of Neutrophil Extracellular Traps. Sur Chowdhury C, Hahn S, Hasler P, Hoesli I, Lapaire O, Giaglis S. *Fetal Diagn Ther* 2016;40:263-267.
62. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Wirz EG, Jaeger VK, Allanore Y, Riemekasten G, Hachulla E, Distler O, Airò P, Carreira PE, Tikly M, Vettori S, Balbir Gurman A, Damjanov N, Müller-Ladner U, Distler J, Li M, Häusermann P, Walker UA; EUSTAR coauthors. *Ann Rheum Dis* 2016;75:1285-92.
63. The "NET Outcome": Are neutrophil extracellular traps of any relevance to the pathophysiology of autoimmune disorders in childhood? Giaglis S, Hahn S, Hasler P. *Front Pediatr* 2016 Sep 13;4:97.
64. Neutrophil extracellular traps in health and disease. Hasler P, Giaglis S, Hahn S. *Swiss Med Wkly* 2016 Oct 10;146:w14352.

65. Surgical versus conservative treatment for lumbar disc herniation: A Prospective Cohort Study. Marinella Gugliotta, Bruno R. da Costa, Essam Dabis, Robert Theiler, Peter Jüni, Stephan Reichenbach, Hans Landolt, Paul Hasler. *BMJ Open* 2016 Dec 21;6(12):e012938.
66. Multimodal regulation of NET formation in pregnancy: Progesterone antagonizes the pro-NETotic effect of estrogen and G-CSF. Giaglis S, Stoikou M, Sur Chowdhury C, Schaefer G, Grimalizzi F, Rossi SW, Hoesli IM, Lapaire O, Hasler P, Hahn S. *Front Immunol* 2016 Dec 5;7:565.
67. An international survey on non-invasive techniques to assess the microcirculation in patients with Raynaud's phenomenon (SUNSHINE survey). Ingegnoli F, Ughi N, Dinsdale G, Orenti A, Boracchi P, Allanore Y et al; EULAR Study Group on Microcirculation in Rheumatic Diseases. *Rheumatol Int* 2017;37:1879-1890.
68. Gestational diabetes mellitus is associated with altered neutrophil activity. Stoikou M, Grimalizzi F, Giaglis S, Schäfer G, van Breda SV, Hoesli IM, Lapaire O, Huhn EA, Hasler P, Rossi SW, Hahn S. *Front Immunol* 2017;8:702.
69. Rheumatoid arthritis: from basic findings and clinical manifestations to future therapies. Hasler P, Gabay C. *Semin Immunopathol* 2017;39:339-341.
70. Update of EULAR recommendations for the treatment of systemic sclerosis. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirkaj L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U; EUSTAR Coauthors. *Ann Rheum Dis* 2017;76:1327-1339.
71. A multidisciplinary DELPHI-consensus-based checklist to define clinical documentation tools both for routine and research purposes. Veraar C, Schirmer M, Hasler P. *Health Serv Res Manag Epidemiol*. 2018 6;5:2333392817754161
72. Markers of Neutrophil Extracellular Traps Predict Adverse Outcome in Community-Acquired Pneumonia Secondary Analysis of a Randomised Controlled Trial. Ebrahimi F, Giaglis S, Hahn S, Blum CA, Baumgartner C, Kutz A, van Breda SV, Mueller B, Schütz P, Christ-Crain M, Hasler P. *Eur Respir J*. 2018 pii: 1701389.
73. Excessive Neutrophil Activity in Gestational Diabetes Mellitus: Could It Contribute to the Development of Preeclampsia? Vokalova L, van Breda SV, Ye XL, Huhn EA, Than NG, Hasler P, Lapaire O, Hoesli I, Rossi SW, Hahn S. *Front Endocrinol (Lausanne)* 2018 Sep 21;9: e0208275.
74. The role of neutrophil activation in determining the outcome of pregnancy and modulation by hormones and/or cytokines. Hahn S, Hasler P, Vokalova L, van Breda SV, Lapaire O, Than GN, Hoesli I, Rossi SW. *Clin Exp Immunol* 2019 doi: 10.1111/cei.13278.
75. Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases – a prospective multi-centre cohort study. Bühler S, Jaeger VK, Adler S, Bannert B, Brümmerhoff C, Ciurea A, Distler O, Franz J, Gabay C, Hagenbuch N, Herzog C, Hasler P, Kling K, Kyburz D, Müller R, Nissen MJ, Siegrist CA, Villiger PM, Walker UA, Hatz C. *Rheumatology (Oxford)*. 2019 Mar 15. pii: kez045.
76. Feto-Maternal Microchimerism: The Pre-eclampsia Conundrum. Hahn S, Hasler P, Vokalova L, van Breda SV, Than NG, Hoesli IM, Lapaire O, Rossi SW. *Front Immunol* 2019 doi.org/10.3389.
77. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Ricciari V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network. *Ann Rheum Dis* 2019 pii: annrheumdis-2018-214816
78. Computational methodologies for the quantification of neutrophil extracellular traps. van Breda SV, Vokalova L, Neugebauer C, Rossi SW, Hahn S, Hasler P. *Front Immunol*. 2019 doi.org/10.3389/fimmu.2019.01562
79. Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau cohorts. Mueller RB, Hasler C, Popp F, Mattow F, Durmisi M, Souza A, Hasler P, Rubbert-Roth A, Schulze-Koops H, von Kempis J. *J Clin Med*. 2019;8:1548: doi:10.3390/jcm8101548
80. Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals. Burkhard J, Ciurea A, Gabay C, Hasler P, Müller R, Niedrig M, Fehr J, Villiger P, Visser LG, de Visser AW, Walker UA, Hatz C, Bühler S. *Vaccine* 2020;38:3610-3617.
81. Pain relief and gain of function from low dose radiotherapy for epicondylitis, finger polyarthritis and plantar fasciitis. Rogers S, Eberle B, Vogt D, Meier E, Moser L, Gomez S, Desborough S, Riesterer O, Takacs I, Hasler P, Bodis S. *Front. Med*. doi: 10.3389/fmed.2020.00195.
82. Longterm immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals. Burkhard J, Ciurea A, Gabay C, Hasler P, Müller R, Niedrig M, Fehr J, Villiger P, Visser LG, de Visser AW, Walker UA, Hatz C, Bühler S. *Vaccine* 2020, 38(19):3610-3617.
83. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. Finckh A, Tellenbach C, Herzog L, Scherer A, Moeller B, Ciurea A, von Muehlenen I, Gabay C, Kyburz D, Brulhart L, Müller R, Hasler P, Zufferey P. *RMD Open* 2020, 6(1).
84. Rheumatoid Arthritis from Pathogenesis to Therapeutic Strategies. Mueller RB, Hasler P. *J Clin Med* 2020, 9.

85. Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational study. Schmid N, Ciurea A, Gabay C, Hasler P, Fehr J, Muller R, Villiger P, Walker U, Hatz C, Buhler S: *Travel Med Infect Dis* 2020, 38:101818.
86. Rheumatoid Arthritis from Pathogenesis to Therapeutic Strategies. Mueller RB, Hasler P. *J Clin Med* 2020, 9.
87. Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational study. Schmid N, Ciurea A, Gabay C, Hasler P, Fehr J, Muller R, Villiger P, Walker U, Hatz C, Buhler S. *Travel Med Infect Dis* 2020, 38:101818.
88. Prospective Evaluation of Changes in Pain Levels, Quality of Life and Functionality After Low Dose Radiotherapy for Epicondylitis, Plantar Fasciitis, and Finger Osteoarthritis. Rogers S, Eberle B, Vogt DR, Meier E, Moser L, Gomez Ordenez S, Desborough S, Riesterer O, Takacs I, Hasler P, Bodis S. *Front Med (Lausanne)* 2020, 7:195.
89. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. Finckh A, Tellenbach C, Herzog L, Scherer A, Moeller B, Ciurea A, von Muehlenen I, Gabay C, Kyburz D, Brulhart L, et al. *RMD Open* 2020, 6.
90. Current practice of transitional care for adolescents and young adults in Swiss paediatric and adult rheumatology centres. Berben L, Sigg N, Daly ML, Bachmann S, Baer W, Berthet G, Bolt I, Dan D, Enderlin Steiger S, Frohlich J, Hasler P, Hofer M, Huemer C, Kaiser D, Marcoli N, Palmer Sarott S, Rottlander Y, Schmid G, Soennichsen C, Strahm Furler L, Vanoni F, Wildi L, Daikeler T, Woerner A. *Swiss Med Wkly* 2021, 151:w30046.
91. Circulatory Neutrophils Exhibit Enhanced Neutrophil Extracellular Trap Formation in Early Puerperium: NETs at the Nexus of Thrombosis and Immunity. Giaglis S, Sur Chowdhury C, van Breda SV, Stoikou M, Tiaden AN, Daoudlarian D, Schaefer G, Buser A, Walker UA, Lapaire O, Hoesli I, Hasler P, Hahn S. *Int J Mol Sci* 2021, 22(24).
92. The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort. Hernandez J, Jordan S, Dobrota R, Iudici M, Hasler P, Ribl C, Villiger P, Vlachoyiannopoulos P, Vacca A, Garzanova L, Giollo A, Rosato E, Kotter I, Carreira PE, Doria A, Henes J, Muller-Ladner U, Smith V, Distler O. *The Eustar Consortium. Swiss Med Wkly* 2021, 151:w20528.
93. Effect of Anti-Inflammatory Diets on Pain in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Schoenenberger KA, Schupfer AC, Gloy VL, Hasler P, Stanga Z, Kaegi-Braun N, Reber E. *Nutrients* 2021, 13(12).
94. Successful Treatment of Rheumatoid Meningitis Associated with a decrease of ACPA Antibody Index. Rubeli S, Conen C, Diepers M, Bernasconi L, Hasler P, Müller R. *J Clin Rheumatol* 2022;28:e667.
95. Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls. Mischlinger J, Jaeger VK, Ciurea A, Gabay C, Hasler P, Mueller RB, Siegrist CA, Villiger P, Walker UA, Hatz C, Bühler S. *Vaccine*. 2022;40:4897-4904.
96. Can the complex, multifactorial gait disorder of a 28-year-old patient be significantly improved? Truschkat A, Poller M, Berli M, Hasler P. *Praxis* 2022, in press.
97. Serious infection risk of tofacitinib compared to biologics inpatients with rheumatoid arthritis treated in routine clinical care. Riek M, Scherer A, Möller B, Ciurea A, von Muehlenen I, Gabay C, Kyburz D, Brulhart L, von Kempis J, Mueller RB, Hasler P, Strahm T, von Känel S, Zufferey P, Dudler J, Finckh A. *Sci Report* 2023;13:17776.
98. Therapeutic management of systemic sclerosis patients – an analysis from the Swiss cohort. Windirsch K, Jordan S, Becker MO, Bruni C, Dobrota R, Elhai M, Garaiman IA, Mihai CM, Iudici M, **Hasler P**, Ribl C, Maurer B, Gabrielli A, Hoffmann-Vold AM, Distler O. *Swiss Med Wkly* 2024;154:3630.
1. r P. (2003). *Rheumatology* 43:116.